Resource Summary Report

Generated by NIF on Sep 1, 2026

Netherlands Brain Bank

RRID:SCR_013841
Type: Tool

Proper Citation

Netherlands Brain Bank (RRID:SCR_013841)

Resource Information

URL: http://www.brainbank.nl

Proper Citation: Netherlands Brain Bank (RRID:SCR_013841)

Description: A biomaterial supply resource which collects, stores, and disseminates diseased and healthy brain tissue. The Netherlands Brain Bank currently contains more than 3600 samples, and each sample includes a neuropathological report and donor medical history. The samples can additionally be matched with ante-mortem parameters and post-mortem parameters upon request. Sample types include cortex, spinal cord, cerebrospinal fluid, plasma, and DNA, among others. Database mining is available with a financial contribution.

Abbreviations: NBB

Resource Type: biomaterial supply resource, material resource

Keywords: biomaterial supply resource, brain, brain tissue, brain bank, diseased tissue, healthy tissue, FASEB list

Funding: Stichting MS Research ;
Vrienden Loterij ;
Stichting Parkinson Fonds ;
Hersenstichting Nederland Breinbekend Werk ;
Zabawas ;
private donations

Availability: Free, Available to the research community, The community can contribute to this resource, Some services require a contribution

Resource Name: Netherlands Brain Bank

Resource ID: SCR_013841

Record Creation Time: 20220129T080318+0000

Record Last Update: 20260829T183106+0000

Ratings and Alerts

No rating or validation information has been found for Netherlands Brain Bank.

No alerts have been found for Netherlands Brain Bank.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 186 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Mueller A, et al. (2026) In-vitro interaction studies between the amyloid PET tracer florbetaben and the amyloid-beta targeting antibodies lecanemab and donanemab on AD brain samples reveal no interferences. Alzheimer's research & therapy, 18(1).

Arafa D, et al. (2026) Myelin sheaths in the central nervous system can withstand damage and dynamically remodel. Science (New York, N.Y.), 391(6786), eadr4661.

Ruf WP, et al. (2026) Multi-modal dissection of cell-type specific TDP-43 pathology in the motor cortex. Nature communications, 17(1).

Engelenburg HJ, et al. (2026) Protocol for isolating viable human central nervous system T cells. STAR protocols, 7(2), 104464.

Dunot J, et al. (2026) AETA peptide contributes to Alzheimer's disease signature of synapse dysfunction. Acta neuropathologica, 151(1).

Leboeuf M, et al. (2026) Reevaluating the role of beta2-microglobulin: new insights on selective vulnerability in ALS pathology. Acta neuropathologica, 151(1).

Zachrisson O, et al. (2026) Exidavnemab binds to aggregated ?-synuclein in human brains affected by ?-synucleinopathies. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 23(1), e00779.

Bolsewig K, et al. (2026) A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders. Nature medicine, 32(3), 1073.

Honey MIJ, et al. (2026) An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration. Nature medicine, 32(6), 2083.

Preitner N, et al. (2026) Elimination of tau tangles and soluble aggregates with the small molecule ACI-16664 prevents neurodegeneration in vivo. Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(7), e71572.

Stellingwerf A, et al. (2026) Evaluating Basigin as a Potential Biomarker of Blood-Brain Barrier Dysfunction in Cerebral Amyloid Angiopathy. Neuropathology and applied neurobiology, 52(1), e70064.

Klavert J, et al. (2026) Charting the human-specific properties of gene expression networks in the infant prefrontal cortex. Science advances, 12(23), eaea3316.

Müller-Schiffmann A, et al. (2025) Oxidized MIF is an Alzheimer's disease drug target relaying external risk factors to tau pathology. Cell reports. Medicine, 102520.

Ciccaldo M, et al. (2025) A novel allosteric GCase modulator prevents Tau accumulation in GBA1WT and GBA1L444P/L444P cellular models. Scientific reports, 15(1), 17646.

Rocha FM, et al. (2025) Mapping reactive astrogliosis in Parkinson's brain with astroglial tracers BU99008 and Deprenyl: New insights from a multi-marker postmortem study. Alzheimer's & dementia : the journal of the Alzheimer's Association, 21(2), e14488.

Theologidis V, et al. (2025) Bradykinesia and postural instability in a model of prodromal synucleinopathy with ?-synuclein aggregation initiated in the gigantocellular nuclei. Acta neuropathologica communications, 13(1), 32.

Ivan T, et al. (2025) Aggregation-Dependent Epitope Sequence and Modification Fingerprints of Anti-A? Antibodies. bioRxiv : the preprint server for biology.

Vokali E, et al. (2025) Development of [18F]ACI-19626 as a first-in-class brain PET tracer for imaging TDP-43 pathology. Nature communications, 16(1), 9358.

Weidling I, et al. (2025) hiPSC-neurons recapitulate the subtype-specific cell intrinsic nature of susceptibility to neurodegenerative disease-relevant aggregation. Acta neuropathologica communications, 13(1), 108.

Orr N, et al. (2025) Epstein-Barr virus and the immune microenvironment in multiple sclerosis: Insights from high-dimensional brain tissue imaging. Proceedings of the National Academy of Sciences of the United States of America, 122(11), e2425670122.